ClinicalTrials.gg
CompletedNCT01591460Updated Nov 2, 2016Results posted

A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C

A Phase 4 interventional study of boceprevir and peginterferon alfa-2a [Pegasys] in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
165
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.

Enrollment
35th of 83
165 · median 129
Started
2012
with 6 others
Phase 4
48 of 83
none open now
Registered
70th of 83
by date
Lead sponsor
35 of 83
Hoffmann-La Roche

Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 35th largest by enrollment, is one of 7 that started in 2012, is one of 48 in phase 4, and was the 70th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic as a file.
02

Study summary

This open-label, multicenter, treatment response guided study will evaluate the sustained virological response and safety of the triple combination therapy boceprevir, Pegasys (peginterferon alfa-2a) and Copegus (Ribavirin) in previously untreated patients with genotype 1 chronic hepatitis C. In the lead-in phase, patients will receive a dual combination therapy of Pegasys and Copegus for 4 weeks. In the following triple combination therapy phase, 800 mg boceprevir, 180 mcg Pegasys and 1000-1200 mg Copegus will be administered for 24, 32 or 44 weeks; the duration depending on the patient's treatment response. The anticipated time on study treatment is up to 48 weeks.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients >/=18 years of age
  • Chronic liver disease consistent with chronic , genotype 1 infection
  • Serum HCV RNA quantifiable at screening
  • Patients who have not been previously treated with pegylated interferon (IFN), standard IFN, RBV or any direct acting anti-viral agent
  • Compensated liver disease ( Grade A clinical classification for patients with cirrhosis: total score \</=6)
  • Negative urine or blood pregnancy test (for women of )

Exclusion criteria

Exclusion Criteria:

  • Women with ongoing pregnancy or breast feeding
  • Male partners of women who are pregnant
  • Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment \</=6 months prior to the first dose of study drug
  • Any drug \</=6 weeks prior to the first dose of study drug
  • History or other evidence of decompensated liver disease
  • History or other evidence of a medical condition associated with chronic liver disease other than chronic
  • Signs or symptoms of hepatocellular carcinoma
  • Co-infection with HCV genotypes other than genotype 1
  • Co-infection with hepatitis A, , and/or (HIV)
  • Any patient with an increased risk for anemia
  • History of severe psychiatric disease
  • History of immunologically mediated, chronic pulmonary, or severe cardiac disease
  • Current diseases that are not adequately controlled
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    Dual Combination Therapy

    Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin (Copegus]

  • Experimental
    Triple Combination Therapy

    Drug: boceprevir · Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin (Copegus]

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virological Response (SVR) at 12 Weeks After End of Treatment (EOT)

    SVR at 12 weeks after EOT was defined as an undetectable HCV RNA viral load obtained 12 weeks following completion of treatment. HCV RNA viral load was measured using the Roche COBAS TaqMan 2.0 HCV Test, with a lower limit of detection (LOD) of 10 to 15 international units per milliliter (IU/mL). The percentage of participants with SVR was calculated as \[number of participants with undetectable HCV RNA at 12 weeks after EOT divided by the number of participants analyzed\] multiplied by 100.

    Time frame: At 12 weeks after EOT (up to 60 weeks)

Secondary outcomes

  1. Percentage of Participants With SVR at 24 Weeks After EOT

    SVR at 24 weeks after EOT was defined as an undetectable HCV RNA viral load obtained 24 weeks following completion of treatment. HCV RNA viral load was measured using the Roche COBAS TaqMan 2.0 HCV Test, with a lower LOD of 10 to 15 IU/mL. The percentage of participants with SVR was calculated as \[number of participants with undetectable HCV RNA at 24 weeks after EOT divided by the number of participants analyzed\] multiplied by 100.

    Time frame: At 24 weeks after EOT (up to 72 weeks)

  2. HCV RNA Levels

    HCV RNA levels were obtained routinely during and after treatment. Mean HCV RNA levels were calculated by averaging the HCV RNA levels among all participants analyzed at each collection timepoint and expressed in log10 IU/mL.

    Time frame: At Baseline; Weeks 2, 4, 6, 8, 12, 16, 24, 28, and 36; EOT; and 12 and 24 weeks after EOT (up to 72 weeks)

  3. Percentage of Participants With Virological Response

    HCV RNA levels were obtained routinely during and after treatment. The percentage of participants with undetectable HCV RNA viral load (ie, virological response) was calculated as \[number of participants with undetectable HCV RNA at each timepoint divided by the number of participants analyzed\] multiplied by 100.

    Time frame: At Weeks 2, 4, 6, 8, 12, 16, 24, 28, and 36; and EOT (up to 48 weeks)

  4. Percentage of Participants With at Least a 1-Log, 2-Log, or 3-Log Reduction in HCV RNA

    HCV RNA levels were obtained routinely during and after treatment. Reductions in HCV RNA viral load by 1-log, 2-log, or 3-log increments were determined relative to Baseline HCV RNA. Each increment represents a reduction greater than or equal to (≥) the specified log value, including results for which HCV RNA was below the limit of quantification (25 IU/mL). The percentage of participants with each log reduction in HCV RNA was calculated as \[number of participants with log reduction divided by the number of participants analyzed\] multiplied by 100.

    Time frame: At Weeks 2, 4, 6, 8, 12, 16, 24, and 28

  5. Percentage of Participants With Virological Relapse Following EOT Response

    Virological relapse was defined as a detectable post-treatment HCV RNA viral load following a previously undetectable EOT level (ie, virological response). The percentage of participants with virological relapse was calculated as \[number of participants meeting the above criteria divided by the number of participants analyzed\] multiplied by 100.

    Time frame: Up to 72 weeks (at 12 and 24 weeks after EOT)

  6. Percentage of Participants With Virological Breakthrough Following On-Treatment Response

    Virological breakthrough was defined as an HCV RNA viral load greater than (\>) 1000 IU/mL following a previously undetectable level at any time during treatment (ie, virological response). Participants who ultimately achieved an EOT response were not considered for virological breakthrough. The percentage of participants with virological breakthrough was calculated as \[number of participants meeting the above criteria divided by the number of participants analyzed\] multiplied by 100.

    Time frame: Up to 48 weeks (at Baseline; Weeks 2, 4, 6, 8, 12, 16, 24, 28, and 36; and EOT)

  7. Percentage of Participants With Virological Rebound Following On-Treatment Decline in HCV RNA

    Virological rebound was defined as an HCV RNA viral load \>1000 IU/mL and a ≥1-log increase from nadir following a decline in HCV RNA from Baseline at any time during treatment (ie, on-treatment decline). Participants who ultimately achieved an EOT response were not considered for virological rebound. The percentage of participants with virological rebound was calculated as \[number of participants meeting the above criteria divided by the number of participants analyzed\] multiplied by 100.

    Time frame: Up to 48 weeks (at Baseline; Weeks 2, 4, 6, 8, 12, 16, 24, 28, and 36; and EOT)

  8. Percentage of Participants With Treatment Discontinued Based Upon Elevated (Week 12) or Detectable (Week 24) HCV RNA

    Treatment was to be discontinued for participants who met prespecified criteria, termed the futility rule, after 12 or 24 weeks of treatment. Participants were discontinued from treatment for one of the following reasons: HCV RNA viral load ≥100 IU/mL (Week 12) or a detectable HCV RNA viral load (Week 24). HCV RNA viral load was measured using the Roche COBAS TaqMan 2.0 HCV Test, with a lower LOD of 10 to 15 IU/mL. The percentage of participants with treatment discontinued for each reason was calculated as \[number of participants meeting one of the above criteria divided by the number of participants analyzed\] multiplied by 100.

    Time frame: At 12 and 24 weeks

  9. Duration of Treatment With PEG-IFN, RBV, and Boceprevir

    The duration of treatment with each study drug was determined as the time from treatment start until the last dose of PEG-IFN, RBV, or boceprevir. Median duration of treatment was determined using the actual duration of treatment among individual participants and expressed in weeks.

    Time frame: Up to 48 weeks (from Baseline until EOT)

  10. Percentage of Participants With a Dose Modification of PEG-IFN, RBV, or Boceprevir By Reason

    Dose modifications for each study drug included any dose reduction, treatment interruption, or premature withdrawal. Adverse event (AE)-related reasons were documented, as well as reasons related to insufficient efficacy ('Poor efficacy') or other safety-related reasons ('Safety/other'). The percentage of participants with a dose modification documented for each reason was calculated as \[number of participants with dose modification divided by the number of participants analyzed\] multiplied by 100.

    Time frame: Up to 48 weeks (from Baseline until EOT)

  11. Percentage of Participants Receiving Target Administrations of PEG-IFN, RBV, and Boceprevir

    The frequency of missed treatments was examined using the number of administrations received as a percentage of target administrations for each study drug. The maximum number of possible administrations was considered in terms of once-weekly injections with PEG-IFN and in terms of treatment days with RBV and boceprevir. The percentage of target administrations each participant received was separated into ranges of \<60%, 60 to \<80%, 80 to \<95%, and ≥95% for each study drug. The percentage of participants who received each range of target administrations was calculated as \[number of participants in each range divided by the number of participants analyzed\] multiplied by 100.

    Time frame: Up to 48 weeks (from Baseline until EOT)

  12. Number of Participants With a Safety-Related Dose Modification

    Dose modifications for each study drug included any dose reduction, treatment interruption, or premature withdrawal. The percentage of participants with a safety-related dose modification (eg, modification due to adverse event or laboratory abnormality) of any study drug was calculated as \[number of participants with dose modification divided by the number of participants analyzed\] multiplied by 100.

    Time frame: Up to 48 weeks (from Baseline until EOT)

  13. Time to Safety-Related Dose Modification

    Dose modifications for each study drug included any dose reduction, treatment interruption, or premature withdrawal. Median time to safety-related dose modification (eg, modification due to adverse event or laboratory abnormality) of any study drug was estimated using Kaplan-Meier and expressed in weeks.

    Time frame: Up to 48 weeks (from Baseline until EOT)

  14. Percentage of Participants Using Concomitant Hematopoietic Stimulants During Treatment and Follow-Up

    Use of concomitant hematopoietic stimulants (such as epoetin) during the 48-week treatment period and/or within 24 weeks of follow-up was documented. The percentage of participants using concomitant hematopoietic stimulants was calculated as \[number of participants reporting concomitant use divided by the number of participants analyzed\] multiplied by 100.

    Time frame: Up to 72 weeks (from Baseline until 24 weeks after EOT)

  15. Percentage of Participants With a Concomitant Disease Prior to or During the Study

    The prevalence of concomitant disease at any time from Screening through the end of follow-up was documented. The percentage of participants with a concomitant disease was calculated as \[number of participants reporting or diagnosed with concomitant disease divided by the number of participants analyzed\] multiplied by 100. Diseases documented for ≥5% of participants included hypertension, diabetes mellitus, hypothyroidism, and vitamin D deficiency as reported here.

    Time frame: Up to 76 weeks (from Screening until 24 weeks after EOT)

  16. Percentage of Participants Using Concomitant Medications During Treatment and Follow-Up

    Use of concomitant prescription or nonprescription medications during the 48-week treatment period and/or within 24 weeks of follow-up was documented. The percentage of participants using concomitant medications was calculated as \[number of participants reporting concomitant use divided by the number of participants analyzed\] multiplied by 100. Medication classes reported by \>10% of participants included analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), antihistamines, corticosteroids, proton pump inhibitors, vitamins and minerals, and beta-adrenoceptor blocking agents as reported here.

    Time frame: Up to 72 weeks (from Baseline until 24 weeks after EOT)

07

Results

Posted Aug 7, 2015

Participant flow

Participant flow — Overall Study
MilestoneTotal Population
Started165
Completed139
Not completed26
Withdrew: Adverse event or intercurrent illness5
Withdrew: Futility rule (week 12)7
Withdrew: Futility rule (week 24)3
Withdrew: Rebound or breakthrough3
Withdrew: Treatment discontinued by error1
Withdrew: Lost to follow-up1
Withdrew: Noncompliance1
Withdrew: Participant refusal3
Withdrew: Withdrawal by subject1
Withdrew: Protocol violation1

Outcome measures

PrimaryPercentage of Participants With Sustained Virological Response (SVR) at 12 Weeks After End of Treatment (EOT)

SVR at 12 weeks after EOT was defined as an undetectable HCV RNA viral load obtained 12 weeks following completion of treatment. HCV RNA viral load was measured using the Roche COBAS TaqMan 2.0 HCV Test, with a lower limit of detection (LOD) of 10 to 15 international units per milliliter (IU/mL). The percentage of participants with SVR was calculated as \[number of participants with undetectable HCV RNA at 12 weeks after EOT divided by the number of participants analyzed\] multiplied by 100.

Time frame:
At 12 weeks after EOT (up to 60 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virological Response (SVR) at 12 Weeks After End of Treatment (EOT)
percentage of participantsTotal PopulationCirrhoticsPoor RespondersLate RespondersEarly RespondersOthers
Percentage of Participants With Sustained Virological Response (SVR) at 12 Weeks After End of Treatment (EOT)81 (74 to 86)70 (46 to 88)75 (53 to 90)88 (68 to 97)95 (87 to 99)32 (13 to 57)
SecondaryPercentage of Participants With SVR at 24 Weeks After EOT

SVR at 24 weeks after EOT was defined as an undetectable HCV RNA viral load obtained 24 weeks following completion of treatment. HCV RNA viral load was measured using the Roche COBAS TaqMan 2.0 HCV Test, with a lower LOD of 10 to 15 IU/mL. The percentage of participants with SVR was calculated as \[number of participants with undetectable HCV RNA at 24 weeks after EOT divided by the number of participants analyzed\] multiplied by 100.

Time frame:
At 24 weeks after EOT (up to 72 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With SVR at 24 Weeks After EOT
percentage of participantsTotal PopulationCirrhoticsPoor RespondersLate RespondersEarly RespondersOthers
Percentage of Participants With SVR at 24 Weeks After EOT80 (73 to 86)70 (46 to 88)71 (49 to 87)88 (68 to 97)95 (87 to 99)32 (13 to 57)
SecondaryHCV RNA Levels

HCV RNA levels were obtained routinely during and after treatment. Mean HCV RNA levels were calculated by averaging the HCV RNA levels among all participants analyzed at each collection timepoint and expressed in log10 IU/mL.

Time frame:
At Baseline; Weeks 2, 4, 6, 8, 12, 16, 24, 28, and 36; EOT; and 12 and 24 weeks after EOT (up to 72 weeks)
Reported as:
Mean · log10 IU/mL
HCV RNA Levels
log10 IU/mLTotal PopulationCirrhoticsPoor RespondersLate RespondersEarly RespondersOthers
Baseline (n=165,20,24,24,78,19)6.29 ± 0.7226.34 ± 0.7106.40 ± 0.5926.46 ± 0.5306.18 ± 0.7966.34 ± 0.762
Week 2 (n=159,18,24,23,76,18)4.86 ± 1.4185.06 ± 1.2886.07 ± 0.6105.38 ± 0.7674.27 ± 1.4414.90 ± 1.597
Week 4 (n=158,20,24,22,75,17)4.06 ± 1.5254.30 ± 1.5335.78 ± 0.5504.60 ± 0.8743.25 ± 1.2894.24 ± 1.689
Week 6 (n=151,18,24,21,73,15)1.75 ± 0.8822.01 ± 1.0022.70 ± 0.9721.91 ± 0.5701.25 ± 0.1542.18 ± 1.337
Week 8 (n=160,20,24,24,77,15)1.47 ± 0.6381.69 ± 0.6501.95 ± 0.8741.52 ± 0.3291.18 ± 0.0001.84 ± 1.236
Week 12 (n=160,20,24,24,77,15)1.35 ± 0.6821.41 ± 0.3931.69 ± 1.3161.25 ± 0.1071.18 ± 0.0001.74 ± 1.292
Week 16 (n=156,19,22,24,78,13)1.25 ± 0.4051.34 ± 0.4591.46 ± 0.9061.19 ± 0.0451.18 ± 0.0001.32 ± 0.458
Week 24 (n=152,17,23,24,78,10)1.41 ± 1.0421.80 ± 1.7531.83 ± 1.6961.18 ± 0.0001.18 ± 0.0002.21 ± 1.916
Week 28 (n=143,15,19,23,76,10)1.23 ± 0.4801.18 ± 0.0001.45 ± 1.1731.18 ± 0.0001.18 ± 0.0251.48 ± 0.822
Week 36 (n=71,16,21,24,3,7)1.69 ± 1.5631.54 ± 1.4122.00 ± 2.0691.33 ± 0.7452.60 ± 2.4661.91 ± 1.930
EOT (n=162,20,24,23,78,17)1.52 ± 1.1201.58 ± 1.1671.87 ± 1.5631.38 ± 0.9961.18 ± 0.0252.73 ± 1.943
12 weeks after EOT (n=152,19,24,23,74,12)1.92 ± 1.7922.53 ± 2.3402.48 ± 2.3451.48 ± 1.0871.40 ± 0.9463.83 ± 2.789
24 weeks after EOT (n=159,20,23,24,78,14)2.00 ± 1.8742.66 ± 2.3512.39 ± 2.3271.77 ± 1.6051.42 ± 1.0534.05 ± 2.592
SecondaryPercentage of Participants With Virological Response

HCV RNA levels were obtained routinely during and after treatment. The percentage of participants with undetectable HCV RNA viral load (ie, virological response) was calculated as \[number of participants with undetectable HCV RNA at each timepoint divided by the number of participants analyzed\] multiplied by 100.

Time frame:
At Weeks 2, 4, 6, 8, 12, 16, 24, 28, and 36; and EOT (up to 48 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Virological Response
percentage of participantsTotal PopulationCirrhoticsPoor RespondersLate RespondersEarly RespondersOthers
Week 24 (1 to 8)0 (0 to 17)0 (0 to 14)0 (0 to 14)6 (2 to 14)5 (0 to 26)
Week 47 (4 to 12)0 (0 to 17)0 (0 to 14)0 (0 to 14)14 (7 to 24)5 (0 to 26)
Week 641 (34 to 49)35 (15 to 59)0 (0 to 14)4 (0 to 21)71 (59 to 80)26 (9 to 51)
Week 861 (53 to 68)45 (23 to 68)13 (3 to 32)0 (0 to 14)100 (95 to 100)53 (29 to 76)
Week 1282 (75 to 87)65 (41 to 85)75 (53 to 90)67 (45 to 84)100 (95 to 100)53 (29 to 76)
Week 1687 (81 to 91)70 (46 to 88)71 (49 to 87)96 (79 to 100)100 (95 to 100)58 (33 to 80)
Week 2488 (82 to 92)80 (56 to 94)79 (58 to 93)100 (86 to 100)100 (95 to 100)42 (20 to 67)
Week 2887 (81 to 91)80 (56 to 94)79 (58 to 93)96 (79 to 100)99 (93 to 100)42 (20 to 67)
Week 3683 (76 to 88)75 (51 to 91)75 (53 to 90)96 (79 to 100)95 (87 to 99)37 (16 to 62)
EOT87 (81 to 92)80 (56 to 94)79 (58 to 93)96 (79 to 100)99 (93 to 100)47 (24 to 71)
SecondaryPercentage of Participants With at Least a 1-Log, 2-Log, or 3-Log Reduction in HCV RNA

HCV RNA levels were obtained routinely during and after treatment. Reductions in HCV RNA viral load by 1-log, 2-log, or 3-log increments were determined relative to Baseline HCV RNA. Each increment represents a reduction greater than or equal to (≥) the specified log value, including results for which HCV RNA was below the limit of quantification (25 IU/mL). The percentage of participants with each log reduction in HCV RNA was calculated as \[number of participants with log reduction divided by the number of participants analyzed\] multiplied by 100.

Time frame:
At Weeks 2, 4, 6, 8, 12, 16, 24, and 28
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 1-Log, 2-Log, or 3-Log Reduction in HCV RNA
percentage of participantsTotal PopulationCirrhoticsPoor RespondersLate RespondersEarly RespondersOthers
3-log, Week 212 (7 to 17)5 (0 to 25)0 (0 to 14)0 (0 to 14)19 (11 to 30)16 (3 to 40)
3-log, Week 429 (22 to 37)20 (6 to 44)0 (0 to 14)8 (1 to 27)47 (36 to 59)26 (9 to 51)
3-log, Week 688 (82 to 92)85 (62 to 97)75 (53 to 90)92 (73 to 99)97 (91 to 100)63 (38 to 84)
3-log, Week 893 (88 to 97)95 (75 to 100)83 (63 to 95)100 (86 to 100)100 (95 to 100)68 (43 to 87)
3-log, Week 1295 (91 to 98)100 (83 to 100)88 (68 to 97)100 (86 to 100)100 (95 to 100)74 (49 to 91)
3-log, Week 1694 (89 to 97)95 (75 to 100)88 (68 to 97)100 (86 to 100)100 (95 to 100)68 (43 to 87)
3-log, Week 2490 (84 to 94)80 (56 to 94)83 (63 to 95)100 (86 to 100)100 (95 to 100)53 (29 to 76)
3-log, Week 2888 (83 to 93)80 (56 to 94)79 (58 to 93)96 (79 to 100)100 (95 to 100)53 (29 to 76)
2-log, Week 227 (20 to 34)20 (6 to 44)0 (0 to 14)8 (1 to 27)42 (31 to 54)26 (9 to 51)
2-log, Week 451 (43 to 59)50 (27 to 73)0 (0 to 14)33 (16 to 55)76 (65 to 85)37 (16 to 62)
2-log, Week 695 (90 to 97)95 (75 to 100)96 (79 to 100)96 (79 to 100)99 (93 to 100)74 (49 to 91)
2-log, Week 897 (93 to 99)100 (83 to 100)100 (86 to 100)100 (86 to 100)100 (95 to 100)74 (49 to 91)
2-log, Week 1295 (91 to 98)100 (83 to 100)88 (68 to 97)100 (86 to 100)100 (95 to 100)74 (49 to 91)
2-log, Week 1694 (89 to 97)95 (75 to 100)88 (68 to 97)100 (86 to 100)100 (95 to 100)68 (43 to 87)
2-log, Week 2490 (84 to 94)80 (56 to 94)83 (63 to 95)100 (86 to 100)100 (95 to 100)53 (29 to 76)
2-log, Week 2888 (83 to 93)80 (56 to 94)79 (58 to 93)96 (79 to 100)100 (95 to 100)53 (29 to 76)
1-log, Week 255 (47 to 62)60 (36 to 81)0 (0 to 14)54 (33 to 74)73 (62 to 82)42 (20 to 67)
1-log, Week 481 (74 to 86)75 (51 to 91)0 (0 to 14)100 (86 to 100)100 (95 to 100)84 (60 to 97)
1-log, Week 698 (94 to 99)95 (75 to 100)100 (86 to 100)100 (86 to 100)100 (95 to 100)84 (60 to 97)
1-log, Week 898 (95 to 100)100 (83 to 100)100 (86 to 100)100 (86 to 100)100 (95 to 100)84 (60 to 97)
1-log, Week 1296 (92 to 99)100 (83 to 100)96 (79 to 100)100 (86 to 100)100 (95 to 100)74 (49 to 91)
1-log, Week 1694 (89 to 97)95 (75 to 100)88 (68 to 97)100 (86 to 100)100 (95 to 100)68 (43 to 87)
1-log, Week 2491 (85 to 95)80 (56 to 94)88 (68 to 97)100 (86 to 100)100 (95 to 100)58 (33 to 80)
1-log, Week 2888 (83 to 93)80 (56 to 94)79 (58 to 93)96 (79 to 100)100 (95 to 100)53 (29 to 76)
SecondaryPercentage of Participants With Virological Relapse Following EOT Response

Virological relapse was defined as a detectable post-treatment HCV RNA viral load following a previously undetectable EOT level (ie, virological response). The percentage of participants with virological relapse was calculated as \[number of participants meeting the above criteria divided by the number of participants analyzed\] multiplied by 100.

Time frame:
Up to 72 weeks (at 12 and 24 weeks after EOT)
Reported as:
Number · percentage of participants
Percentage of Participants With Virological Relapse Following EOT Response
percentage of participantsTotal PopulationCirrhoticsPoor RespondersLate RespondersEarly RespondersOthers
Percentage of Participants With Virological Relapse Following EOT Response7 (3 to 12)13 (2 to 38)5 (0 to 26)9 (1 to 28)4 (1 to 11)25 (3 to 65)
SecondaryPercentage of Participants With Virological Breakthrough Following On-Treatment Response

Virological breakthrough was defined as an HCV RNA viral load greater than (\>) 1000 IU/mL following a previously undetectable level at any time during treatment (ie, virological response). Participants who ultimately achieved an EOT response were not considered for virological breakthrough. The percentage of participants with virological breakthrough was calculated as \[number of participants meeting the above criteria divided by the number of participants analyzed\] multiplied by 100.

Time frame:
Up to 48 weeks (at Baseline; Weeks 2, 4, 6, 8, 12, 16, 24, 28, and 36; and EOT)
Reported as:
Number · percentage of participants
Percentage of Participants With Virological Breakthrough Following On-Treatment Response
percentage of participantsTotal PopulationCirrhoticsPoor RespondersLate RespondersEarly RespondersOthers
Percentage of Participants With Virological Breakthrough Following On-Treatment Response3 (1 to 7)0 (0 to 20)0 (0 to 18)4 (0 to 21)0 (0 to 5)23 (5 to 54)
SecondaryPercentage of Participants With Virological Rebound Following On-Treatment Decline in HCV RNA

Virological rebound was defined as an HCV RNA viral load \>1000 IU/mL and a ≥1-log increase from nadir following a decline in HCV RNA from Baseline at any time during treatment (ie, on-treatment decline). Participants who ultimately achieved an EOT response were not considered for virological rebound. The percentage of participants with virological rebound was calculated as \[number of participants meeting the above criteria divided by the number of participants analyzed\] multiplied by 100.

Time frame:
Up to 48 weeks (at Baseline; Weeks 2, 4, 6, 8, 12, 16, 24, 28, and 36; and EOT)
Reported as:
Number · percentage of participants
Percentage of Participants With Virological Rebound Following On-Treatment Decline in HCV RNA
percentage of participantsTotal PopulationCirrhoticsPoor RespondersLate RespondersEarly RespondersOthers
Percentage of Participants With Virological Rebound Following On-Treatment Decline in HCV RNA6 (3 to 11)5 (0 to 25)17 (5 to 37)4 (0 to 21)0 (0 to 5)22 (6 to 48)
SecondaryPercentage of Participants With Treatment Discontinued Based Upon Elevated (Week 12) or Detectable (Week 24) HCV RNA

Treatment was to be discontinued for participants who met prespecified criteria, termed the futility rule, after 12 or 24 weeks of treatment. Participants were discontinued from treatment for one of the following reasons: HCV RNA viral load ≥100 IU/mL (Week 12) or a detectable HCV RNA viral load (Week 24). HCV RNA viral load was measured using the Roche COBAS TaqMan 2.0 HCV Test, with a lower LOD of 10 to 15 IU/mL. The percentage of participants with treatment discontinued for each reason was calculated as \[number of participants meeting one of the above criteria divided by the number of participants analyzed\] multiplied by 100.

Time frame:
At 12 and 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Discontinued Based Upon Elevated (Week 12) or Detectable (Week 24) HCV RNA
percentage of participantsTotal PopulationCirrhoticsPoor RespondersLate RespondersEarly RespondersOthers
Week 12410130011
Week 243580011
SecondaryDuration of Treatment With PEG-IFN, RBV, and Boceprevir

The duration of treatment with each study drug was determined as the time from treatment start until the last dose of PEG-IFN, RBV, or boceprevir. Median duration of treatment was determined using the actual duration of treatment among individual participants and expressed in weeks.

Time frame:
Up to 48 weeks (from Baseline until EOT)
Reported as:
Median · weeks
Duration of Treatment With PEG-IFN, RBV, and Boceprevir
weeksTotal PopulationCirrhoticsPoor RespondersLate RespondersEarly RespondersOthers
PEG-IFN (n=165,20,24,24,78,19)28.0 (1 to 49)48.0 (14 to 48)48.0 (13 to 49)48.0 (32 to 48)28.0 (24 to 32)26.0 (1 to 48)
RBV (n=165,20,24,24,78,19)28.0 (1 to 49)48.0 (13 to 48)48.0 (14 to 49)48.0 (30 to 49)28.0 (10 to 33)27.0 (1 to 48)
Boceprevir (n=164,20,24,24,78,18)24.0 (1 to 45)44.0 (8 to 44)44.0 (10 to 45)32.0 (2 to 33)24.0 (6 to 25)10.0 (1 to 44)
SecondaryPercentage of Participants With a Dose Modification of PEG-IFN, RBV, or Boceprevir By Reason

Dose modifications for each study drug included any dose reduction, treatment interruption, or premature withdrawal. Adverse event (AE)-related reasons were documented, as well as reasons related to insufficient efficacy ('Poor efficacy') or other safety-related reasons ('Safety/other'). The percentage of participants with a dose modification documented for each reason was calculated as \[number of participants with dose modification divided by the number of participants analyzed\] multiplied by 100.

Time frame:
Up to 48 weeks (from Baseline until EOT)
Reported as:
Number · percentage of participants
Percentage of Participants With a Dose Modification of PEG-IFN, RBV, or Boceprevir By Reason
percentage of participantsTotal PopulationCirrhoticsPoor RespondersLate RespondersEarly RespondersOthers
PEG-IFN, Any reason (n=165,20,24,24,78,19)526054464284
PEG-IFN, Anemia (n=165,20,24,24,78,19)100015
PEG-IFN, Asthenia (n=165,20,24,24,78,19)104400
PEG-IFN, Nausea/vomiting (n=165,20,24,24,78,19)0.600010
PEG-IFN, Neutropenia (n=165,20,24,24,78,19)363038333647
PEG-IFN, Rash (n=165,20,24,24,78,19)0.650000
PEG-IFN, Thrombocytopenia (n=165,20,24,24,78,19)5354010
PEG-IFN, Safety/other (n=165,20,24,24,78,19)41041300
PEG-IFN, Poor efficacy (n=165,20,24,24,78,19)815214021
PEG-IFN, Not specified (n=165,20,24,24,78,19)120813842
RBV, Any reason (n=165,20,24,24,78,19)646567466289
RBV, Anemia (n=165,20,24,24,78,19)465046385326
RBV, Asthenia (n=165,20,24,24,78,19)0.600010
RBV, Nausea/vomiting (n=165,20,24,24,78,19)1000011
RBV, Neutropenia (n=165,20,24,24,78,19)3004021
RBV, Rash (n=165,20,24,24,78,19)150005
RBV, Safety/other (n=165,20,24,24,78,19)815813316
RBV, Poor efficacy (n=165,20,24,24,78,19)815214021
RBV, Not specified (n=165,20,24,24,78,19)11088842
Boceprevir, Any reason (n=164,20,24,24,78,18)284529211289
Boceprevir, Anemia (n=164,20,24,24,78,18)2100400
Boceprevir, Asthenia (n=164,20,24,24,78,18)0.600010
Boceprevir, Nausea/vomiting (n=164,20,24,24,78,18)1000011
Boceprevir, Neutropenia (n=164,20,24,24,78,18)4004028
Boceprevir, Rash (n=164,20,24,24,78,18)150006
Boceprevir, Safety/other (n=164,20,24,24,78,18)41004017
Boceprevir, Poor efficacy (n=164,20,24,24,78,18)715210017
Boceprevir, Not specified (n=164,20,24,24,78,18)1210881028
SecondaryPercentage of Participants Receiving Target Administrations of PEG-IFN, RBV, and Boceprevir

The frequency of missed treatments was examined using the number of administrations received as a percentage of target administrations for each study drug. The maximum number of possible administrations was considered in terms of once-weekly injections with PEG-IFN and in terms of treatment days with RBV and boceprevir. The percentage of target administrations each participant received was separated into ranges of \<60%, 60 to \<80%, 80 to \<95%, and ≥95% for each study drug. The percentage of participants who received each range of target administrations was calculated as \[number of participants in each range divided by the number of participants analyzed\] multiplied by 100.

Time frame:
Up to 48 weeks (from Baseline until EOT)
Reported as:
Number · percentage of participants
Percentage of Participants Receiving Target Administrations of PEG-IFN, RBV, and Boceprevir
percentage of participantsTotal PopulationCirrhoticsPoor RespondersLate RespondersEarly Responders
PEG-IFN, <60%8252500
PEG-IFN, 60 to <80%0.70040
PEG-IFN, 80 to <95%550174
PEG-IFN, 95% or more8670757996
RBV, <60%9252541
RBV, 60 to <80%0.70040
RBV, 80 to <95%510084
RBV, 95% or more8665758395
Boceprevir, <60%10302581
Boceprevir, 60 to <80%0.75000
Boceprevir, 80 to <95%35043
Boceprevir, 95% or more8660758896
SecondaryNumber of Participants With a Safety-Related Dose Modification

Dose modifications for each study drug included any dose reduction, treatment interruption, or premature withdrawal. The percentage of participants with a safety-related dose modification (eg, modification due to adverse event or laboratory abnormality) of any study drug was calculated as \[number of participants with dose modification divided by the number of participants analyzed\] multiplied by 100.

Time frame:
Up to 48 weeks (from Baseline until EOT)
Reported as:
Number · participants
Number of Participants With a Safety-Related Dose Modification
participantsTotal Population
Number of Participants With a Safety-Related Dose Modification113
SecondaryTime to Safety-Related Dose Modification

Dose modifications for each study drug included any dose reduction, treatment interruption, or premature withdrawal. Median time to safety-related dose modification (eg, modification due to adverse event or laboratory abnormality) of any study drug was estimated using Kaplan-Meier and expressed in weeks.

Time frame:
Up to 48 weeks (from Baseline until EOT)
Reported as:
Median · weeks
Time to Safety-Related Dose Modification
weeksTotal Population
Time to Safety-Related Dose Modification12.1 (10.3 to 16.0)
SecondaryPercentage of Participants Using Concomitant Hematopoietic Stimulants During Treatment and Follow-Up

Use of concomitant hematopoietic stimulants (such as epoetin) during the 48-week treatment period and/or within 24 weeks of follow-up was documented. The percentage of participants using concomitant hematopoietic stimulants was calculated as \[number of participants reporting concomitant use divided by the number of participants analyzed\] multiplied by 100.

Time frame:
Up to 72 weeks (from Baseline until 24 weeks after EOT)
Reported as:
Number · percentage of participants
Percentage of Participants Using Concomitant Hematopoietic Stimulants During Treatment and Follow-Up
percentage of participantsTotal Population
Percentage of Participants Using Concomitant Hematopoietic Stimulants During Treatment and Follow-Up6
SecondaryPercentage of Participants With a Concomitant Disease Prior to or During the Study

The prevalence of concomitant disease at any time from Screening through the end of follow-up was documented. The percentage of participants with a concomitant disease was calculated as \[number of participants reporting or diagnosed with concomitant disease divided by the number of participants analyzed\] multiplied by 100. Diseases documented for ≥5% of participants included hypertension, diabetes mellitus, hypothyroidism, and vitamin D deficiency as reported here.

Time frame:
Up to 76 weeks (from Screening until 24 weeks after EOT)
Reported as:
Number · percentage of participants
Percentage of Participants With a Concomitant Disease Prior to or During the Study
percentage of participantsTotal Population
Any disease53
Hypertension18
Diabetes mellitus8
Hypothyroidism6
Vitamin D deficiency5
SecondaryPercentage of Participants Using Concomitant Medications During Treatment and Follow-Up

Use of concomitant prescription or nonprescription medications during the 48-week treatment period and/or within 24 weeks of follow-up was documented. The percentage of participants using concomitant medications was calculated as \[number of participants reporting concomitant use divided by the number of participants analyzed\] multiplied by 100. Medication classes reported by \>10% of participants included analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), antihistamines, corticosteroids, proton pump inhibitors, vitamins and minerals, and beta-adrenoceptor blocking agents as reported here.

Time frame:
Up to 72 weeks (from Baseline until 24 weeks after EOT)
Reported as:
Number · percentage of participants
Percentage of Participants Using Concomitant Medications During Treatment and Follow-Up
percentage of participantsTotal Population
Any medication79
Analgesics29
NSAIDs22
Antihistamines19
Corticosteroids19
Proton pump inhibitors17
Vitamins and minerals12
Beta-adrenoceptor blocking agents11

Adverse events

Collected over Up to 72 weeks (from Baseline until 24 weeks after EOT). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cirrhotics (Safety)—7/21 (33.3%)21/21 (100%)
Noncirrhotics (Safety)—8/144 (5.6%)135/144 (93.8%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventCirrhotics (Safety)Noncirrhotics (Safety)
AnaemiaBlood and lymphatic system disorders2/212/144
Hepatic failureHepatobiliary disorders2/210/144
ThrombocytopeniaBlood and lymphatic system disorders1/210/144
Hepatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/210/144
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/210/144
PsoriasisSkin and subcutaneous tissue disorders1/210/144
GranulocytopeniaBlood and lymphatic system disorders0/211/144
NeutropeniaBlood and lymphatic system disorders0/211/144
FatigueGeneral disorders0/211/144
OverdoseInjury, poisoning and procedural complications0/211/144
Most frequent other events
Showing 10 of 30
Most frequent other events
EventCirrhotics (Safety)Noncirrhotics (Safety)
AnaemiaBlood and lymphatic system disorders7/2157/144
AstheniaGeneral disorders7/2140/144
NeutropeniaBlood and lymphatic system disorders5/2147/144
DysgeusiaNervous system disorders6/2145/144
Influenza like illnessGeneral disorders6/2134/144
ThrombocytopeniaBlood and lymphatic system disorders6/2113/144
HeadacheNervous system disorders2/2132/144
FatigueGeneral disorders4/2131/144
CoughRespiratory, thoracic and mediastinal disorders3/2131/144
PruritusSkin and subcutaneous tissue disorders4/2130/144

Baseline characteristics

All-Treated Population: All enrolled participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)Total Population
Mean45.8 ± 12.53
Gender
Gender(Participants)Total Population
Female83
Male82
08

Study locations

32 sites
  • Graz, 8036, Austria
  • Innsbruck, 6020, Austria
  • Linz, 4010, Austria
  • Wien, 1090, Austria
  • Wien, 1100, Austria
  • Wien, 1160, Austria
  • Dortmund, 44263, Germany
  • Frankfurt am Main, 60594, Germany
  • Hamburg, 20099, Germany
  • Hannover, 30625, Germany
  • Oberhausen, 46145, Germany
  • Budapest, 1088, Hungary
  • Budapest, 1097, Hungary
  • Budapest, 1126, Hungary
  • Debrecen, 4032, Hungary
  • Kaposvar, 7400, Hungary
  • Pecs, 7624, Hungary
  • Bialystok, 15-540, Poland
  • Bydgoszcz, 85-030, Poland
  • Chorzow, 41-500, Poland
  • Lublin, 20-081, Poland
  • Wrocław, 50-349, Poland
  • Łodz, 91-347, Poland
  • Bucharest, 021105, Romania
  • Bucharest, 022328, Romania
  • Bucharest, 030303, Romania
  • Constanta, 900635, Romania
  • Timisoara, 300167, Romania
  • Vigo, Pontevedra 36200, Spain
  • Baracaldo, Vizcaya 48903, Spain
  • Granada, 18012, Spain
  • Zaragoza, 50009, Spain
09

References and documents

Publications

  • Ferenci P, Caruntu FA, Lengyel G, Messinger D, Bakalos G, Flisiak R. Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial. Infect Dis Ther. 2016 Jun;5(2):113-24. doi: 10.1007/s40121-016-0110-5. Epub 2016 May 26. PubMed 27228998 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2012
First posted
May 4, 2012
Start
Aug 2012
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Results first posted
Aug 7, 2015
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01591460
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 4, 2012
Start date
Aug 2012
Primary completion
Jun 2014
Completion
Jun 2014
Results posted
Aug 7, 2015
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion